Comparison of an ELISA and an LC/MS/MS Method for Measuring Tacrolimus Concentrations and Making Dosage Decisions in Transplant Recipients
Authors:
- Christine E. StaatzCSChristine E. Staatz
- Paul J. TaylorPTPaul J. Taylor
- Susan E. TettSTSusan E. Tett
- 1 October 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 24 (5) , 607-615
Abstract
This study compared an enzyme-linked immunosorbent assay (ELISA) to a liquid chromatography–tandem mass spectrometry (LC/MS/MS) technique for measurement of tacrolimus concentrations in adult kidney and liver transplant recipients, and investigated how assay choice influenced pharmacokinetic parameter estimates and drug dosage decisions. Tacrolimus concentrations measured by both ELISA and LC/MS/MS from 29 kidney (n = 98 samples) and 27 liver (n = 97 samples) transplant recipients were used to evaluate the performance of these methods in the clinical setting. Tacrolimus concentrations measured by the two techniques were compared via regression analysis. Population pharmacokinetic models were developed independently using ELISA and LC/MS/MS data from 76 kidney recipients. Derived kinetic parameters were used to formulate “typical dosing” regimens for concentration targeting. Dosage recommendations for the two assays were compared. The relation between LC/MS/MS and ELISA measurements was best described by the regression equation ELISA = 1.02 · (LC/MS/MS) + 0.14 in kidney recipients, and ELISA = 1.12 · (LC/MS/MS) − 0.87 in liver recipients. ELISA displayed less accuracy than LC/MS/MS at lower tacrolimus concentrations. Population pharmacokinetic models based on ELISA and LC/MS/MS data were similar with residual random errors of 4.1 ng/mL and 3.7 ng/mL, respectively. Assay choice gave rise to dosage prediction differences ranging from 0% to 30%. ELISA measurements of tacrolimus are not automatically interchangeable with LC/MS/MS values. Assay differences were greatest in adult liver recipients, probably reflecting periods of liver dysfunction and impaired biliary secretion of metabolites. While the majority of data collected in this study suggested assay differences in adult kidney recipients were minimal, findings of ELISA dosage underpredictions of up to 25% in the long term must be investigated further.Keywords
This publication has 32 references indexed in Scilit:
- Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography—tandem mass-spectrometryClinical Biochemistry, 2001
- Automated, fast and sensitive quantification of drugs in blood by liquid chromatography–mass spectrometry with on-line extraction: immunosuppressantsJournal of Chromatography B: Biomedical Sciences and Applications, 2000
- TacrolimusDrugs, 2000
- Therapeutic Drug Monitoring of Tacrolimus (FK506) Using Tandem Mass SpectrometryTherapeutic Drug Monitoring, 1998
- An HPLC/MS/MS assay for tacrolimus in patient blood samples Correlation with results of an ELISA assayJournal of Pharmaceutical and Biomedical Analysis, 1997
- A Specific Method for the Measurement of Tacrolimus in Human Whole Blood by Liquid Chromatography/Tandem Mass SpectrometryTherapeutic Drug Monitoring, 1997
- Measurement of Tacrolimus (FK506) and Its MetabolitesTherapeutic Drug Monitoring, 1997
- Consensus Document: Therapeutic Monitoring of Tacrolimus (FK-506)Therapeutic Drug Monitoring, 1995
- Analysis of Tacrolimus (FK 506) in Relation to Therapeutic Drug MonitoringTherapeutic Drug Monitoring, 1995
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995